Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2007 (2007), Article ID 93573, 8 pages
http://dx.doi.org/10.1155/2007/93573
Research Article

Association of C-Reactive Protein, Interleukin-1 Receptor Antagonist and Adiponectin with the Metabolic Syndrome

1Department of Internal Medicine, Central Hospital of Middle Finland, Jyväskylä 40620, Finland
2Department of General Medicine, Central Hospital of Middle Finland, Jyväskylä 40620, Finland
3Laukaa Health Center, Laukaa 41341, Finland
4Medcare Foundation, Äänekoski 44100, Finland
5Department of Public Health and Clinical Nutrition, University of Kuopio, Kuopio 70211, Finland
6Unit of General Practice, Kuopio University Hospital, Kuopio 70211, Finland
7Department of Medicine, University of Kuopio, Kuopio 70211, Finland

Received 6 July 2007; Accepted 29 August 2007

Copyright © 2007 Juha Saltevo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. World Health Orgnization, “Definition, diagnosis and classification of diabetes mellitus and its complications,” Tech. Rep. 99.2, World Health Orgnization, Geneva, Switzerland, 1999. View at Google Scholar
  2. “Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III),” Journal of the American Medical Association, vol. 285, no. 19, pp. 2486–2497, 2001. View at Publisher · View at Google Scholar
  3. S. M. Grundy, B. Hansen, S. C. Smith Jr., J. I. Cleeman, and R. A. Kahn, “Clinical management of metabolic syndrome: report of the American heart association/national heart, lung, and blood institute/American diabetes association conference on scientific issues related to management,” Circulation, vol. 109, no. 4, pp. 551–556, 2004. View at Publisher · View at Google Scholar
  4. International Diabetes Federation, “The IDF consensus worldwide definition of the metabolic syndrome,” October 2005, http://www.idf.org/webdata/docs/metac_syndrome_def.pdf.
  5. K. G. M. M. Alberti, P. Zimmet, and J. Shaw, “The metabolic syndrome: a new worldwide definition,” The Lancet, vol. 366, no. 9491, pp. 1059–1062, 2005. View at Publisher · View at Google Scholar
  6. C. Weyer, T. Funahashi, S. Tanaka et al., “Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia,” Journal of Clinical Endocrinology & Metabolism, vol. 86, no. 5, pp. 1930–1935, 2001. View at Publisher · View at Google Scholar
  7. Y. Matsuzawa, “Adipocytokines and metabolic syndrome,” Seminars in Vascular Medicine, vol. 5, no. 1, pp. 34–39, 2005. View at Publisher · View at Google Scholar
  8. T. Kadowaki and T. Yamauchi, “Adiponectin and adiponectin receptors,” Endocrine Reviews, vol. 26, no. 3, pp. 439–451, 2005. View at Publisher · View at Google Scholar
  9. J. C. Pickup and M. A. Crook, “Is type II diabetes mellitus a disease of the innate immune system?” Diabetologia, vol. 41, no. 10, pp. 1241–1248, 1998. View at Publisher · View at Google Scholar
  10. A. J. G. Hanley, A. Festa, R. B. D'Agostino Jr. et al., “Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity,” Diabetes, vol. 53, no. 7, pp. 1773–1781, 2004. View at Publisher · View at Google Scholar
  11. P. M. Ridker, “Clinical application of C-reactive protein for cardiovascular disease detection and prevention,” Circulation, vol. 107, no. 3, pp. 363–369, 2003. View at Publisher · View at Google Scholar
  12. D. E. Laaksonen, L. Niskanen, K. Nyyssönen, K. Punnonen, T.-P. Tuomainen, and J. T. Salonen, “C-reactive protein in the prediction of cardiovascular and overall mortality in middle-aged men: a population-based cohort study,” European Heart Journal, vol. 26, no. 17, pp. 1783–1789, 2005. View at Publisher · View at Google Scholar
  13. M. Soinio, J. Marniemi, M. Laakso, S. Lehto, and T. Rönnemaa, “High-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes,” Diabetes Care, vol. 29, no. 2, pp. 329–333, 2006. View at Publisher · View at Google Scholar
  14. D. E. Laaksonen, L. Niskanen, K. Nyyssönen et al., “C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men,” Diabetologia, vol. 47, no. 8, pp. 1403–1410, 2004. View at Publisher · View at Google Scholar
  15. A. D. Pradhan, J. E. Manson, N. Rifai, J. E. Buring, and P. M. Ridker, “C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus,” Journal of the American Medical Association, vol. 286, no. 3, pp. 327–334, 2001. View at Publisher · View at Google Scholar
  16. P. M. Ridker, N. Rifai, L. Rose, J. E. Buring, and N. R. Cook, “Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events,” The New England Journal of Medicine, vol. 347, no. 20, pp. 1557–1565, 2002. View at Publisher · View at Google Scholar
  17. N. Sattar, A. Gaw, O. Scherbakova et al., “Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the west of Scotland coronary prevention study,” Circulation, vol. 108, no. 4, pp. 414–419, 2003. View at Publisher · View at Google Scholar
  18. M. Hassinen, T. A. Lakka, P. Komulainen, H. Gylling, A. Nissinen, and R. Rauramaa, “C-reactive protein and metabolic syndrome in elderly women: a 12-year follow-up study,” Diabetes Care, vol. 29, no. 4, pp. 931–932, 2006. View at Publisher · View at Google Scholar
  19. S. M. Haffner, “The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease,” The American Journal of Cardiology, vol. 97, no. 2, supplement 1, pp. 3–11, 2006. View at Publisher · View at Google Scholar
  20. P. M. Ridker, “C-reactive protein, inflammation, and cardiovascular disease: clinical update,” Texas Heart Institute Journal, vol. 32, no. 3, pp. 384–386, 2005. View at Google Scholar
  21. C. Gabay and I. Kushner, “Acute-phase proteins and other systemic responses to inflammation,” The New England Journal of Medicine, vol. 340, no. 6, pp. 448–454, 1999. View at Publisher · View at Google Scholar
  22. U. Salmenniemi, E. Ruotsalainen, and J. Pihlajamäki, “Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome,” Circulation, vol. 110, no. 25, pp. 3842–3848, 2004. View at Publisher · View at Google Scholar
  23. G. Patti, A. D'Ambrosio, A. Dobrina et al., “Interleukin-1 receptor antagonist: a sensitive marker of instability in patients with coronary artery disease,” Journal of Thrombosis and Thrombolysis, vol. 14, no. 2, pp. 139–143, 2002. View at Publisher · View at Google Scholar
  24. A. Katz, S. S. Nambi, K. Mather et al., “Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans,” Journal of Clinical Endocrinology & Metabolism, vol. 85, no. 7, pp. 2402–2410, 2000. View at Publisher · View at Google Scholar
  25. P. H. Westfall, R. D. Tobias, D. Rom, R. D. Wolfinger, and Y. Hochberg, Multiple Comparisons and Multiple Tests Using the SAS System, SAS Institute, Cary, NC, USA, 1999.
  26. J. R. Landis and G. G. Koch, “The measurement of observer agreement for categorical data,” Biometrics, vol. 33, no. 1, pp. 159–174, 1977. View at Publisher · View at Google Scholar
  27. M.-S. Lin, S.-R. Shih, H.-Y. Li et al., “Serum C-reactive protein levels correlates better to metabolic syndrome defined by international diabetes federation than by NCEP ATP III in men,” Diabetes Research and Clinical Practice, vol. 77, no. 2, pp. 286–292, 2007. View at Publisher · View at Google Scholar
  28. C. Lorenzo, K. Williams, K. J. Hunt, and S. M. Haffner, “The national cholesterol education program-adult treatment panel III, international diabetes federation, and world health organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes,” Diabetes Care, vol. 30, no. 1, pp. 8–13, 2007. View at Publisher · View at Google Scholar
  29. Y. Okamoto, S. Kihara, T. Funahashi, Y. Matsuzawa, and P. Libby, “Adiponectin: a key adipocytokine in metabolic syndrome,” Clinical Science, vol. 110, no. 3, pp. 267–278, 2006. View at Google Scholar
  30. S. E. Kahn, B. Zinman, S. M. Haffner et al., “Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes,” Diabetes, vol. 55, no. 8, pp. 2357–2364, 2006. View at Publisher · View at Google Scholar
  31. J.-P. Després, “Abdominal obesity: the most prevalent cause of the metabolic syndrome and related cardiometabolic risk,” European Heart Journal Supplements, vol. 8, supplement B, pp. B4–B12, 2006. View at Publisher · View at Google Scholar
  32. Y. Wang, E. B. Rimm, M. J. Stampfer, W. C. Willett, and F. B. Hu, “Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men,” American Journal of Clinical Nutrition, vol. 81, no. 3, pp. 555–563, 2005. View at Google Scholar
  33. M. A. Banerji, N. Faridi, R. Atluri, R. L. Chaiken, and H. E. Lebovitz, “Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men,” Journal of Clinical Endocrinology & Metabolism, vol. 84, no. 1, pp. 137–144, 1999. View at Publisher · View at Google Scholar
  34. A. Festa, R. D'Agostino Jr., G. Howard, L. Mykkänen, R. P. Tracy, and S. M. Haffner, “Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS),” Circulation, vol. 102, no. 1, pp. 42–47, 2000. View at Google Scholar
  35. S. Ishikawa, K. Kayaba, T. Gotoh, Y. Nakamura, and E. Kajii, “Metabolic syndrome and C-reactive protein in the general population: JMS cohort study,” Circulation Journal, vol. 71, no. 1, pp. 26–31, 2007. View at Publisher · View at Google Scholar
  36. M. Santaniemi, Y. A. Kesäniemi, and O. Ukkola, “Low plasma adiponectin concentration is an indicator of the metabolic syndrome,” European Journal of Endocrinology, vol. 155, no. 5, pp. 745–750, 2006. View at Publisher · View at Google Scholar
  37. K. Matsushita, K. Tamakoshi, H. Yatsuya et al., “Further inflammatory information on metabolic syndrome by adiponectin evaluation,” preprint, International Journal of Cardiology, 2007.
  38. F. M. Adam, M. J. Nara, and J. M. Adam, “Fasting insulin, adiponectin, hs-CRP levels and the components of metabolic syndrome,” Acta Medica Indonesiana, vol. 38, no. 4, pp. 179–184, 2006. View at Google Scholar
  39. G. Q. Shaibi, M. L. Cruz, M. J. Weigensberg et al., “Adiponectin independently predicts metabolic syndrome in overweight Latino youth,” Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 5, pp. 1809–1813, 2007. View at Publisher · View at Google Scholar
  40. C. Herder, M. Peltonen, W. Koenig et al., “Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes,” Diabetes, vol. 55, no. 8, pp. 2340–2346, 2006. View at Publisher · View at Google Scholar
  41. E. Ruotsalainen, U. Salmenniemi, I. Vauhkonen et al., “Changes in inflammatory cytokines are related to impaired glucose tolerance in offspring of type 2 diabetic subjects,” Diabetes Care, vol. 29, no. 12, pp. 2714–2720, 2006. View at Publisher · View at Google Scholar
  42. W. P. Arend and C. Gabay, “Physiologic role of interleukin-1 receptor antagonist,” Arthritis Research, vol. 2, no. 4, pp. 245–248, 2000. View at Publisher · View at Google Scholar
  43. P. Ilanne-Parikka, J. G. Eriksson, J. Lindström et al., “Prevalence of the metabolic syndrome and its components: findings from a Finnish general population sample and the Diabetes Prevention Study cohort,” Diabetes Care, vol. 27, no. 9, pp. 2135–2140, 2004. View at Publisher · View at Google Scholar
  44. C. Lara-Castro, N. Luo, P. Wallace, R. L. Klein, and W. T. Garvey, “Adiponectin multimeric complexes and the metabolic syndrome trait cluster,” Diabetes, vol. 55, no. 1, pp. 249–259, 2006. View at Publisher · View at Google Scholar
  45. K. Hara, M. Horikoshi, T. Yamauchi et al., “Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome,” Diabetes Care, vol. 29, no. 6, pp. 1357–1362, 2006. View at Publisher · View at Google Scholar